

References

This is the reference list for the ACE Clinical Guideline “Osteoporosis: diagnosis and management”.

1. Shen Y, Huang X, Wu J, et al. The Global Burden of Osteoporosis, Low Bone Mass, and Its Related Fracture in 204 Countries and Territories, 1990-2019. *Front Endocrinol* 2022; 13: 882241.
2. Ministry of Health Singapore. Incidence of hip and non-hip fracture-related healthcare utilisation in men and women from 2017 to 2022. *Unpublished*.
3. Yong EL, Ganesan G, Kramer MS, et al. Hip fractures in Singapore: ethnic differences and temporal trends in the new millennium. *Osteoporos Int* 2019; 30(4): 879–886.
4. Lau SSM, Koh SWC, Lui YS. Managing unhealthy alcohol use in general practice. *Singapore Med J*. 2021; 62(2): 69–74.
5. Chan SP, Teo CC, Ng SA, et al. Validation of various osteoporosis risk indices in elderly Chinese females in Singapore. *Osteoporos Int* 2006; 17(8): 1182–1188.
6. Subramaniam S, Ima-Nirwana S, Chin KY. Performance of Osteoporosis Self-Assessment Tool (OST) in predicting osteoporosis: a review. *Int J Environ Res Public Health* 2018; 15(7): 1445.
7. Chandran M, Chin YA, Choo KS, et al. Comparison of the Osteoporosis Self-Assessment Tool for Asians and the fracture risk assessment tool - FRAX to identify densitometric defined osteoporosis: a discriminatory value analysis in a multi-ethnic female population in Southeast Asia. *Osteoporos Sarcopenia* 2020; 6(2): 53–58.
8. Koh LK, Sedrine WB, Torralba TP, et al. A simple tool to identify Asian women at increased risk of osteoporosis. *Osteoporos Int* 2001; 12(8): 699–705.
9. Ministry of Health Malaysia. Clinical practice guidelines: management of osteoporosis. 3rd ed. Malaysia: MOH; 2022.
10. Kanis JA, Harvey NC, Cooper C, et al. A systematic review of intervention thresholds based on FRAX: a report for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. *Arch Osteoporos* 2016; 11(1): 25.
11. Kanis JA, Chandran M, Chionh SB, et al. Use of age-dependent FRAX-based intervention thresholds for Singapore. *Arch Osteoporos* 2020; 15(1): 104.
12. Hereford T, Kellish A, Samora JB, et al. Understanding the importance of peak bone mass. *J Pediatr Orthop Soc North Am* 2024; 7: 100031.
13. Health Promotion Board. Recommended dietary allowances [Internet]. Singapore: HealthHub SG; [cited 2025 Mar 31]. Available from: <https://www.healthhub.sg/live-healthy/recommended-dietary-allowances>
14. Gani LU, How CH. Vitamin D deficiency. *Singapore Med J*. 2015; 56(8): 433–437.
15. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. *Endocr Pract* 2020; 26(Suppl 1): 1–46.
16. US Preventive Services Task Force. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. *JAMA*. 2025; 333(6): 498–508.
17. Scottish Intercollegiate Guidelines Network (SIGN). Management of osteoporosis and the prevention of fragility fractures. SIGN publication no. 142. Edinburgh: SIGN; 2021.
18. Royal Australian College of General Practitioners. Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age. East Melbourne: RACGP; 2024.
19. Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. *Arch Osteoporos* 2022; 17(1): 58.

20. Diacinti D, Guglielmi G. How to define an osteoporotic vertebral fracture? *Quant Imaging Med Surg* 2019; 9(9): 1485–1494.
21. Checa-Betegón P, Luque-Pérez R, Oñate-Martínez-Olascoaga D, et al. [Translated article] Osteoporotic vertebral fractures: Natural history and impact. *Rev Esp Cir Ortop Traumatol* 2024; 68(6): T587–T596.
22. Harris K, Zagar CA, Lawrence KV. Osteoporosis: common questions and answers. *Am Fam Physician* 2023; 107(3): 238–246.
23. Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. *Ther Adv Musculoskelet Dis* 2014; 6(5): 185–202.
24. Varacallo MA, Seaman TJ, Jandu JS, et al. Osteopenia [Updated 2023 Aug 4]. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
25. Schini M, Johansson H, Harvey NC, et al. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. *J Endocrinol Invest* 2024; 47(3): 501–511.
26. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2019; 104(5): 1595–1622.
27. American College of Obstetricians and Gynecologists. Management of postmenopausal osteoporosis: ACOG clinical practice guideline no. 2. *Obstet Gynecol* 2022; 139(4): 698–717.
28. Qaseem A, Hicks LA, Etzeandia-Ikobaltzeta I, et al. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. *Ann Intern Med* 2023; 176(2): 224–238.
29. Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. *J Clin Endocrinol Metab* 2019; 104(5): 1623–1630.
30. Diez-Perez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis. *Osteoporos Int* 2012; 23(12): 2769–2774.
31. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. *Ann Intern Med* 2008; 148(3): 197–213.
32. Rosen HN. Bisphosphonate therapy for the treatment of osteoporosis. In: UpToDate, Connor RF (Ed), Wolters Kluwer. (Accessed on July 18, 2025.)
33. Rosen HN. Denosumab for osteoporosis. In: UpToDate, Connor RF (Ed), Wolters Kluwer. (Accessed on July 18, 2025.)
34. Balasubramanian A, Zhang J, Chen L, et al. Risk of subsequent fracture after prior fracture among older women. *Osteoporos Int* 2019; 30(1): 79–92.
35. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res* 2015; 30(1): 3–23.
36. Gupta M, Gupta N. Bisphosphonate-related jaw osteonecrosis [Updated 2023 Jul 24]. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
37. Penoni DC, Canellas JVS, Silami MANC, et al. Osteonecrosis of the jaws in patients under osteoporosis treatment: a nine-year experience report. *Arch Endocrinol Metab* 2023; 67(4): e000612
38. AlRowis R, Aldawood A, AlOtaibi M, et al. Medication-Related Osteonecrosis of the Jaw (MRONJ): A review of pathophysiology, risk factors, preventive measures and treatment strategies. *Saudi Dent J* 2022; 34(3): 202–210.
39. Scottish Dental Clinical Effectiveness Programme. Oral health management of patients at risk of medication-related osteonecrosis of the jaw. Dundee: SDCEP; 2024.

40. Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws – 2022 update. *J Oral Maxillofac Surg* 2022; 80(5): 920–943.
41. Ishimaru M, Ono S, Morita K, et al. Prevalence, incidence rate, and risk factors of medication-related osteonecrosis of the jaw in patients with osteoporosis and cancer: A nationwide population-based study in Japan. *J Oral Maxillofac Surg* 2022; 80(4): 714–727.
42. Brunner C, Arvandi M, Marth C, et al. Incidence of medication-related osteonecrosis of the jaw in patients with breast cancer during a 20-year follow-up: A population-based multicenter retrospective study. *J Clin Oncol* 2025; 43(2): 180–188.
43. Hellstein JW, Adler RA, Edwards B, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. *J Am Dent Assoc* 2011;1 42(11): 1243–1251.
44. Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. *N Engl J Med* 2020; 383(8): 743–753.
45. Hayes KN, Winter EM, Cadarette SM, et al. Duration of bisphosphonate drug holidays in osteoporosis patients: a narrative review of the evidence and considerations for decision-making. *J Clin Med* 2021; 10(5): 1140.
46. Wang M, Wu YF, Girgis CM. Bisphosphonate drug holidays: Evidence from clinical trials and real-world studies. *JBMR Plus* 2022; 6(6): e10629.
47. Diab DL, Watts NB. Bisphosphonate drug holiday: who, when and how long. *Ther Adv Musculoskelet Dis* 2013; 5(3): 107–111.
48. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2016; 31(1): 16–35.
49. Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. *J Clin Endocrinol Metab* 2020; dga756
50. Tay WL, Tay D. Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature. *Endocrinol Metab* 2022; 37(2): 183–194.
51. Kendler D, Chines A, Clark P, et al. (2020). Bone Mineral Density After Transitioning From Denosumab to Alendronate. *J Clin Endocrinol Metab* 2020; 105(3): e255–e264.
52. Bandeira L, Lewiecki EM. Anabolic therapy for osteoporosis: update on efficacy and safety. *Arch Endocrinol Metab* 2022; 66(5): 707–716.
53. Vall H, Patel P, Parmar M. Teriparatide [Updated 2024 Feb 29]. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
54. Guyer L, Lehmann O, Wenger M, et al. (2025 Long-term impact of teriparatide on bone mineral density, trabecular bone score, and fracture risk relative to total hip T-score: A two-decade, registry-based cohort study. *Bone* 2025; 195(117445): 117445.
55. Díez-Pérez A, Marin F, Eriksen EF, et al. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis. *Bone* 2019; 120: 1–8.
56. National Osteoporosis Guideline Group (NOGG). Clinical guideline for the prevention and treatment of osteoporosis. London: NOGG; 2024.
57. Wang WY, Chen LH, Ma WJ, et al. Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomised controlled trials. *Eur Rev Med Pharmacol Sci* 2023;2 7(17): 8253–8268.

58. Wei FL, Gao QY, Zhu KL, et al. Efficacy and safety of pharmacologic therapies for prevention of osteoporotic vertebral fractures in postmenopausal women. *Heliyon* 2023; 9(2): e11880.
59. Huang W, Nagao M, Yonemoto N, et al. Evaluation of the efficacy and safety of romosozumab (Evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: a systematic review and meta-analysis of randomised controlled trials (CDM-J). *Pharmacoepidemiol Drug Saf* 2023; 32(6): 671–684.
60. Langdahl B, Hofbauer LC, Ferrari S, et al. Romosozumab efficacy and safety in European patients enrolled in the FRAME trial. *Osteoporos Int* 2022; 33(12): 2527–2536.
61. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. *N Engl J Med* 2017; 377(15): 1417–1427.
62. Rosen CJ. Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis. In: UpToDate, Connor RF (Ed), Wolters Kluwer. (Accessed on July 18, 2025.)
63. Rosen HN, Lewiecki EM. Overview of the management of low bone mass and osteoporosis in postmenopausal women. In: UpToDate, Connor RF (Ed), Wolters Kluwer. (Accessed on July 18, 2025.)
64. Scioscia MF, Zanchetta MB. Recent insights into pregnancy and lactation-associated osteoporosis (PLO). *Int J Womens Health* 2023; 15: 1227–1238.